Literature DB >> 17606435

Mesenchymal stromal cells, from indifferent spectators to principal actors. Are we going to witness a revolution in the scenario of allograft and immune-mediated disorders?

Franco Locatelli, Rita Maccario, Francesco Frassoni.   

Abstract

Mesh：

Year:  2007        PMID： 17606435     DOI： 10.3324/haematol.11479

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  8 in total

1.  Are mesenchymal stromal cells from children resistant to apoptosis?

Authors:  H Dimitriou; Ch Perdikogianni; G Martimianaki; D M Choumerianou; J Pelagiadis; M Kalmanti
Journal:  Cell Prolif       Date:  2009-04-28       Impact factor: 6.831

2.  Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors.

Authors:  Maria Antonietta Avanzini; Maria Ester Bernardo; Angela Maria Cometa; Cesare Perotti; Nadia Zaffaroni; Francesca Novara; Livia Visai; Antonia Moretta; Claudia Del Fante; Raffaella Villa; Lynne M Ball; Willem E Fibbe; Rita Maccario; Franco Locatelli
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

3.  Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients.

Authors:  Philippe M Campeau; Moutih Rafei; Moïra François; Elena Birman; Kathy-Ann Forner; Jacques Galipeau
Journal:  Mol Ther       Date:  2008-12-16       Impact factor: 11.454

4.  Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells.

Authors:  Maria Manuela Rosado; Maria Ester Bernardo; Marco Scarsella; Antonella Conforti; Ezio Giorda; Simone Biagini; Simona Cascioli; Francesca Rossi; Isabella Guzzo; Marina Vivarelli; Luca Dello Strologo; Francesco Emma; Franco Locatelli; Rita Carsetti
Journal:  Stem Cells Dev       Date:  2015-01-01       Impact factor: 3.272

Review 5.  Mesenchymal stem cells for bone repair and metabolic bone diseases.

Authors:  Anita H Undale; Jennifer J Westendorf; Michael J Yaszemski; Sundeep Khosla
Journal:  Mayo Clin Proc       Date:  2009-10       Impact factor: 7.616

Review 6.  Mesenchymal stem/stromal cells: a new ''cells as drugs'' paradigm. Efficacy and critical aspects in cell therapy.

Authors:  Laura de Girolamo; Enrico Lucarelli; Giulio Alessandri; Maria Antonietta Avanzini; Maria Ester Bernardo; Ettore Biagi; Anna Teresa Brini; Giovanna D'Amico; Franca Fagioli; Ivana Ferrero; Franco Locatelli; Rita Maccario; Mario Marazzi; Ornella Parolini; Augusto Pessina; Maria Luisa Torre
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 7.  Preclinical efficacy and mechanisms of mesenchymal stem cells in animal models of autoimmune diseases.

Authors:  Hong Kyung Lee; Sang Hee Lim; In Sung Chung; Yunsoo Park; Mi Jeong Park; Ju Young Kim; Yong Guk Kim; Jin Tae Hong; Youngsoo Kim; Sang-Bae Han
Journal:  Immune Netw       Date:  2014-04-21       Impact factor: 6.303

8.  Targeting of the leukemia microenvironment by c(RGDfV) overcomes the resistance to chemotherapy in acute myeloid leukemia in biomimetic polystyrene scaffolds.

Authors:  Zhao-Hua Shen; Dong-Feng Zeng; Xiao-Yan Wang; Ying-Ying Ma; Xi Zhang; Pei-Yan Kong
Journal:  Oncol Lett       Date:  2016-08-24       Impact factor: 2.967
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.